Jean-Louis Excler

Biographic Data

ID6078903
NAMEJean-Louis Excler
GIVEN NAMESJean-Louis
FAMILY NAMEExcler
SIGNATUREEXCLER J
AFFILIATIONSInternational Vaccine Institute
ORCID0000-0002-6462-5101
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS1
WORKS AS AUTHOR6
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2004
LATEST PUBLICATION YEAR2025
H-INDEX1

  • Estimating the economic burden of invasive non-typhoidal Salmonella infections in low- and middle-income countries

    Open AccessJung-Seok Lee, Yongha Hwang et al.ARTICLEBMJ Global Health2025

    INTRODUCTION: (iNTS) disease is a global health concern, particularly for sub-Saharan Africa. Despite high case fatality risks, there is no vaccine available against the disease. An obstacle to vaccine development is a lack of data on the economic burden of iNTS disease in many parts of the world. The main aim of the current study is to estimate the economic burden of iNTS disease in 123 countries. METHODS: Several multivariate regression models …

  • Mitigating the effects of climate change on human health with vaccines and vaccinations

    Open AccessCara Lynn Kim, Suneth Agampodi et al.ARTICLEFrontiers in Public Health2023

    Climate change represents an unprecedented threat to humanity and will be the ultimate challenge of the 21st century. As a public health consequence, the World Health Organization estimates an additional 250,000 deaths annually by 2030, with resource-poor countries being predominantly affected. Although climate change’s direct and indirect consequences on human health are manifold and far from fully explored, a growing body of evidence demonstrat…

  • Vaccine access, equity and justice

    Open AccessLois Privor-Dumm, Jean-Louis Excler et al.ARTICLEBMJ Global Health2023

    Although significant progress has been made in achieving goals for COVID-19 vaccine access, the quest for equity and justice remains an unfinished agenda. Vaccine nationalism has prompted calls for new approaches to achieve equitable access and justice not only for vaccines but also for vaccination. This includes ensuring country and community participation in global discussions and that local needs to strengthen health systems, address issues re…

  • Covid-19 vaccines and the pandemic

    Open AccessPeter J Hotez, Sarah Gilbert et al.ARTICLEBMJ Global Health2023

    Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a ‘multiple shots on goal’ approach to new vaccine targets. This approach embraces simultaneous development of candidates with differing technologies, including, when feasible, vesicular stomatitis virus or adenovirus vectors, messenger RNA (mRNA), whole inactivated virus, nan…

  • Factors, enablers and challenges for Covid-19 vaccine development

    Open AccessJean-Louis Excler, Melanie Saville et al.ARTICLEBMJ Global Health2023

    The COVID-19 pandemic triggered a sense of vulnerability and urgency that led to concerted actions by governments, funders, regulators and industry to overcome traditional challenges for the development of vaccine candidates and to reach authorisation. Unprecedented financial investments, massive demand, accelerated clinical development and regulatory reviews were among the key factors that contributed to accelerating the development and approval…

  • Research and Development of New Vaccines Against Infectious Diseases

    Marie Paule Kieny, Jean-Louis Excler et al.ARTICLEAmerican Journal of Public Health2004Cited by: 1References: 4

    Infectious diseases are responsible for approximately 25% of global mortality, especially in children aged younger than 5 years. Much of the burden of infectious diseases could be alleviated if appropriate mechanisms could be put in place to ensure access for all children to basic vaccines, regardless of geographical location or economic status. In addition, new safe and effective vaccines should be developed for a variety of infections against w…